firsocostat investigational
Selected indexed studies
- NASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challenges. (Expert Opin Investig Drugs, 2020) [PMID:31984804]
- Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. (Hepatol Commun, 2021) [PMID:34278169]
- GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH). (Expert Opin Investig Drugs, 2020) [PMID:31519114]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. (2021) pubmed
- NASH and NAFLD: emerging drugs, therapeutic targets and translational and clinical challenges. (2020) pubmed
- GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH). (2020) pubmed